INFI News and Press, Infinity Pharmaceuticals Inc. From 04/27/21

Infinity Pharmaceuticals, Inc . (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, to...

SenesTech (SNES) +83% on successful completion of a long term agricultural deployment of ContraPest®ZK International Group (ZKIN) +31%.Marker Therapeutics (MRKR) +28% as as Cantor initiates with high target and insider buying.Clovis Oncology (CLVS) +20% as ARIEL4 study met...

Gainers: Neos Therapeutics (NEOS) +17%,Aytu BioScience (AYTU) +14%, Vericel (VCEL) +14%, Brickell Biotech (BBI) +14%, Infinity Pharmaceuticals (INFI) +13%.Losers: Translate Bio (TBIO) -32%, ContraFect (CFRX) -13%, Lipocine (LPCN...

Yesterday, announcing its interim Phase 1/2 data in patients with cystic fibrosis, Translate Bio (NASDAQ:TBIO) said that MRT5005 did not lead to a marked improvement in lung function. The shares have lost ~27.6% in the premarket as the stock faces downgrades.Today, citing lack ...

Infinity Pharmaceuticals, Inc. (INFI) Q4 2020 Results Conference Call March 16, 2021 04:30 PM ET Company Participants Jayne Kauffman - Senior Executive Coordinator Adelene Perkins - Chairman & CEO Dr. Brian Schwartz - Consulting Chief Physician Larry Bloch - President & Treasurer Conf...

Infinity Pharmaceuticals (INFI) posted a 43% slide in full-year revenue and provided financial forecast for 2021.The company's FY revenue fell 43% to $1.72M, but beat analysts' average estimate by $0.06M.At December 31, 2020, Infinity had total cash, cash equivalents and available-for-sa...

– MARIO-275 data at ASCO GU demonstrate eganelisib benefits across ORR, DCR, and PFS in PD-L1 low, 2L advanced UC patients; planning registration enabling study – – MARIO-3 initial data at SABCS demonstrate tumor reduction in 100% of patients and an ORR of...

This continues our series on busting options myths where we explore a different way to sell options. In this article, we discuss myths around selling puts. These myths generally teach: (i) only sell puts on companies you wouldn't mind owning; (ii) selling puts requires a neutral t...

Infinity Pharmaceuticals, Inc . (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, to...

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, wil...